Harpoon Therapeutics

📍 South San Francisco, United States🗓 Founded 2015👥 55 employees💰 Last funded Jun 2015
Pharmaceutical Manufacturing🌐 harpoontx.com
Website LinkedIn
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. For more information, please visit www.harpoontx.com.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2015
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Harpoon Therapeutics?
Harpoon Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Harpoon Therapeutics last raise funding?
The most recent investment in Harpoon Therapeutics recorded on gritt.io was in June 2015.
When was Harpoon Therapeutics founded?
Harpoon Therapeutics was founded in 2015.
What industry is Harpoon Therapeutics in?
Harpoon Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Harpoon Therapeutics based?
Harpoon Therapeutics is headquartered in South San Francisco, United States.